We value your privacy

We use necessary cookies to make this site work, and Google Analytics to measure visits (it sets cookies and is not affected by the choices below). With your consent, we also use our own analytics cookies to understand how the site is used and improve it. Privacy policy

XOOBAY 数贝环球
金盒集团
金盒集团

金盒集团

Premier Elite

5
Products
0
Followers
2013
Established

Interpretation: How US OTC Achieves Backdoor Listing and Related Notes

Interpretation: How US OTC Achieves Backdoor Listing and Related Notes

Backdoor listings in the U.S. can generally be divided into three types: reverse mergers with traditional mainboard listed companies, the currently booming SPAC model listings, and the most commonly used OTC uplistings.

Traditional mainboard shell companies are extremely rare, and it is difficult to see a mainboard shell company merger even in several years. The SPAC model listing is currently the most popular backdoor listing. It is more efficient than traditional IPOs and has lower listing costs for the merged party. However, to maximize their own profits, the shell sponsors also screen target companies more strictly and cautiously, making it difficult for many target companies to match smoothly with shell companies. Backdoor listings via OTC are the most commonly used method for U.S. backdoor listings due to the abundance of shell resources, but the uneven quality of shell resources will affect the company's reverse merger, name change, and subsequent uplisting.

In general, backdoor listings are more efficient than traditional IPOs, and the success of a backdoor listing largely depends on shell resources. Today we will discuss how to successfully backdoor list via OTC.

1 Overview of the U.S. OTC Market

1.1 Introduction to OTC (Over-the-Counter Market)

The OTC market (Over The Counter) is a broad term, also known as the over-the-counter market or the counter trading market, referring to a market where securities are traded outside of formal stock exchanges. Taking equity securities as an example, the U.S. OTC market has two main quotation mediums: OTCBB (OTC Bulletin Board) and OTC Markets.

OTCBB is managed by the NASD (National Association of Securities Dealers), the operator of NASDAQ, and OTCBB stocks are quoted by market makers through the NASDAQ Workstation II. In fact, there are essential differences between the two. OTCBB is an independent market completely different from NASDAQ; it is neither a NASDAQ market nor a part of NASDAQ or a so-called NASDAQ secondary board. Many Chinese entrepreneurs have been misled into believing that listing on NASDAQ OTCBB is equivalent to listing on NASDAQ.

OTCBB was once very active, but in recent years it has lagged behind OTC Markets in terms of trading and technology, and has gradually been abandoned by the market. OTC Markets Group currently provides a public, transparent, and financially viable trading market for approximately 11,000 small and medium-sized securities issuers in the U.S. and around the world, and it also serves as a platform for companies to uplist to mainboards (NASDAQ, New York Stock Exchange) in the future.

1.2 OTC Market Segmentation and Eligibility Requirements

In 2007, OTC Markets Group acquired Pink Sheets and renamed it OTC Markets, while dividing all listed companies into three tiers: high, medium, and low, namely OTCQX, OTCQB, and OTC Pink.

The OTCQX Best Market is designed for mature, investor-focused U.S. and international companies. To meet the eligibility requirements for the OTCQX market, a company must satisfy high financial standards, follow best practice corporate governance, demonstrate compliance with U.S. securities laws, be current in disclosure, and have a professional third-party sponsor providing liability assurance. Penny stocks, shell companies, and bankrupt companies are not eligible for OTCQX. Companies found on OTCQX are renowned for their operational integrity and due diligence.

The OTCQB Venture Market is designed for early-stage and developing U.S. and international companies. To be eligible, companies must remain current and undergo annual verification and a corporate certification process. Companies must pass the $0.01 bid test and must not be bankrupt.

OTCQX and OTCQB listed companies are all public companies registered with the U.S. Securities and Exchange Commission (SEC), fulfilling the same ongoing disclosure obligations as listed companies on the NYSE and NASDAQ. It is a market regulated by FINRA.

OTC Pink is merely a quotation service system, not an issuer listing and trading system. It provides brokers with a transparent trading platform to achieve best execution in any security. There are no financial standards or disclosure requirements. A wide variety of companies trade on this market, including foreign companies that restrict their U.S. disclosures, penny stocks and shell companies, as well as troubled, debt-laden and "dark" companies that are unwilling or unable to provide information to investors.

2 OTC Reverse Merger (Acquisition) Process

For Chinese companies to become U.S. public companies by reverse merging with an OTC company, the operation usually requires two stages: the first stage is to purchase and obtain controlling equity of the OTC shell company, and the second stage is to inject the target business and assets.

2.1 Selecting a Suitable Shell Company

As mentioned above, the OTC Markets is divided into three segments: OTCQX, OTCQB and OTC Pink. The quality and requirements of listed companies in these three segments vary greatly. Generally, OTC shell acquisition transactions occur in the OTCQB and OTC Pink segments.

Among OTC shell companies, Pink shells are usually hundreds of thousands of U.S. dollars cheaper than QB shells. The disclosure standards and regulatory scales of QB and Pink are different. Pink companies can choose whether to disclose and to which regulatory level to disclose. Based on the level of disclosure regulation, Pink companies are further divided into those that disclose to the SEC (highest requirement), those that disclose to OTC (medium requirement), and those that choose not to disclose (lowest requirement). Generally, the higher the level of disclosure regulation, the more standardized and transparent the company will be.

From the perspective of cost control, acquirers do not necessarily have to choose a QB shell. Not only does it increase transaction costs in the early stage, but after injecting assets, it may also convert from QB to Pink; it is more cost-effective to first buy a relatively high-quality Pink shell and upgrade to QB by submitting forms after injecting assets.

Whether it is a QB or Pink shell, it does not affect the possibility of directly transferring to NASDAQ and NYSE after meeting the requirements in the future. In other words, at the level of transfer operations, QB is not a necessary stage above Pink.

In addition to transaction costs and the operational standardization of the shell company, it is also necessary to consider the original industry and business of the shell company, which is mainly to facilitate "storytelling" for investors. For example, an OTC shell company originally engaged in financial services will be more suitable for injecting fintech and blockchain assets in the future than a trading shell company, making the "story" more reasonable.

2.2 Acquiring Controlling Equity of the Shell Company

Although 51% is sufficient for absolute control, considering the convenience of future asset injection and market value management, etc., OTC merger and acquisition transactions usually transfer 90%-95% of the shares, and a few even transfer 99% of the shares. Due to special reasons, such as scattered OTC shares, or individual minority shareholders refusing to cooperate, being long-term out of contact or deceased, etc., the shares of some OTC shell companies are destined to be difficult to fully trade. The purchaser of the OTC shell should have a reasonable expectation of this.

Before and after the equity transfer of an OTC shell company, the divestiture of part or all of the original shareholders' assets is also involved, which requires a certain amount of time and transaction procedures.

General OTC shell company share transactions can be completed within 2 to 3 months. A certain percentage is paid at the start of the transaction, and the remaining part is paid after the transaction is completed.

2.3 Injection of Target Business and Assets

The injection of target business and assets, commonly known as a "reverse takeover". This stage involves the coordination of multiple intermediary institutions both inside and outside the United States. This business is relatively mature, and the quotations of various institutions are also relatively open and transparent.

Taking the injection of mainland China assets as an example, it is necessary to hire mainland China lawyers, US lawyers, mainland China accounting firms, US auditors, and US securities firms. Depending on the jurisdiction where the injected assets are located, institutions with legal practice qualifications in that jurisdiction or country/region must be hired to issue legal opinions and audit opinions. At present, the fees of overseas lawyers, especially US lawyers and Hong Kong lawyers, are generally much higher than those of mainland China lawyers.

The work of hiring the above institutions is generally arranged by the FA, and the FA will coordinate the fees of various institutions uniformly. Therefore, a relatively large fee is also involved here, namely the FA's fee. The FA's fee is relatively expensive. In addition to charging the normal transaction commission, some FAs will also request OTC original shares and charge an annual maintenance fee.

The time for the asset injection stage varies from person to person and depends on the status of the target business and assets. For example, some assets require a long time for accounting, some businesses need to obtain compliance certificates or special licenses from the place of operation, and if mainland China assets are to be injected, a VIE structure usually needs to be established.

It is recommended that the purchaser organize the assets and business to be injected before proceeding with the share purchase, so that the transaction can be more smooth.

3 Other Relevant Legal Issues and Major Risks

3.1 Potential Debt Risks and Regulatory Risks

Buying and selling OTC shell companies is similar to acquiring equity in other types of companies. The biggest risk is still the potential debts and disputes of the target company. Even if the acquirer's legal and financial due diligence is thorough, it is difficult to exhaust all potential debts and disputes hidden in the specific company's history. These debts may be fraudulent transactions artificially created, or financial loopholes deliberately concealed; these disputes may be sudden tort liabilities, labor claims just arising from transactions, or even regulatory penalties for historical business operations.

Persons in charge of M&A transactions usually require the original shareholders or actual controllers to sign a series of commitments and guarantee clauses. But after receiving the consideration, will the original shareholders and actual controllers maintain their ability to compensate as before? Will the future recovery and claim procedures meet expectations due to issues of territorial jurisdiction and cross-border enforcement?

Another significant risk is the risk of asset injection and accounting. Buyers of OTC shell companies either find it time-consuming to create a new OTC company, or their current assets are not suitable for self-declaration to OTC. If the financial management of the assets to be injected is not standardized enough, a third-party accounting firm needs to be hired to sort out the financial standardization to meet the requirements of issuing audit reports as much as possible. However, not all companies can be sorted out clearly, and not all companies have sufficient transaction records. Therefore, in OTC M&A transactions, the risks of financial standardization and accounting cannot be ignored.

3.2 Issues Regarding the Establishment of a VIE Structure

If the assets intended to be listed on the U.S. OTC market are companies in mainland China, an overseas holding structure needs to be established; if it involves industry sectors where foreign investment is restricted or prohibited by the Chinese government, a VIE structure is also required. The VIE structure is a special structure created in response to compliance requirements in mainland China and the flexibility of U.S. accounting standards at the consolidated financial statement level. Well-known Chinese internet companies such as Sina, Baidu, and Alibaba all successfully listed in the U.S. by establishing a VIE structure.

Of course, if the assets held by a U.S. OTC company actually controlled by Chinese investors are located in regions other than mainland China, such as a winery in Paris, France, or a farm in Australia, there is no need to establish a VIE structure. The equity or other assets of companies in Hong Kong and Macau, China can be directly injected into a U.S. OTC company without a VIE structure.

3.3 Regarding the Shareholder Number Limit of OTC Companies

Domestic investors, even legal professionals, who are more familiar with China's Company Law and Partnership Enterprise Law, often worry whether the OTC company they are trading has a shareholder upper limit threshold like 200 or 300 people. It can be confirmed that neither U.S. federal nor state laws have similar shareholder number requirements. Moreover, OTC companies are already public companies, so this concern about the maximum number of shareholders is unnecessary.

Therefore, many enterprises also develop equity incentives through OTC.

3.4 Impact of the Latest U.S. Regulatory Crackdown on OTC Transactions

The U.S. Senate passed the Holding Foreign Companies Accountable Act on May 20, 2020. The act stipulates that any foreign company that fails to comply with the audit requirements of the Public Company Accounting Oversight Board (PCAOB) for three consecutive years will be prohibited from listing its securities on U.S. stock exchanges. The act will also require listed companies to disclose whether they are owned or controlled by foreign governments. This means that Chinese companies listed in the U.S. (i.e., Chinese concept stocks) face increased delisting risks, and domestic state-owned enterprises will also face obstacles in financing in the U.S. Many people will think that OTC will be hit hard due to the new regulatory policy. In fact, this is not the case.

Chinese concept stocks are share concepts related to investments in mainland China that emerged in the Hong Kong securities market since the 1990s. In the current context, Chinese concept stocks generally refer to companies listed overseas whose main business and assets are located in mainland China. Please note that the premise of the aforementioned "Chinese concept stocks" is "listed companies".

OTC, to some extent, is somewhat similar to China's New Third Board in previous years. It is an over-the-counter market. Therefore, OTC companies will not be significantly affected by the new round of U.S. regulatory crackdown on Chinese concept stocks. OTC transaction demand and transaction frequency will not change much, and may even increase under the new post-pandemic situation.

In fact, at least 35% of the companies that go public on NASDAQ and NYSE in the U.S. each year transfer to NASDAQ or NYSE through OTC. Therefore, OTC is a springboard for enterprises to enter the main board market for listing. However, many people in China have misunderstandings about OTC, thinking that OTC is a scam and only has a stock code. But if your enterprise is still small in scale and does not meet the conditions for NASDAQ IPO, but you want to raise funds to develop the enterprise, what should you do? Then OTC is the best choice for the enterprise. After listing on OTC, the enterprise becomes a public company, and its financing is legal and compliant. Of course, the raised funds must be used for the operation and development of the enterprise. Moreover, on OTC, the company's shares can be deposited and traded in the secondary market. As long as the company develops well, it can also raise funds in the secondary market. With these funds, the enterprise can develop rapidly, and basically, it can transfer to list on NASDAQ in 2-3 years. In fact, U.S. enterprises all operate in this way.

Originally published on 金盒企业管理集团